[CH3:1][N:2]([CH3:29])[CH2:3][CH2:4][NH:5][C:6]1[C:11]([F:12])=[CH:10][CH:9]=[CH:8][C:7]=1[CH:13]1[N:17]([CH2:18][CH2:19][C:20]([CH3:23])([CH3:22])[CH3:21])[C:16](=[O:24])[CH:15]([CH2:25][C:26]([OH:28])=O)[S:14]1.[NH:30]1[CH2:35][CH2:34][CH:33]([N:36]2[C:44]3[C:39](=[N:40][CH:41]=[CH:42][CH:43]=3)[NH:38][C:37]2=[O:45])[CH2:32][CH2:31]1.C(Cl)CCl.C1C=CC2N(O)N=NC=2C=1.CCN(C(C)C)C(C)C>CN(C=O)C.CCOC(C)=O>[CH3:29][N:2]([CH3:1])[CH2:3][CH2:4][NH:5][C:6]1[C:11]([F:12])=[CH:10][CH:9]=[CH:8][C:7]=1[CH:13]1[N:17]([CH2:18][CH2:19][C:20]([CH3:21])([CH3:23])[CH3:22])[C:16](=[O:24])[C@H:15]([CH2:25][C:26]([N:30]2[CH2:31][CH2:32][CH:33]([N:36]3[C:44]4[C:39](=[N:40][CH:41]=[CH:42][CH:43]=4)[NH:38][C:37]3=[O:45])[CH2:34][CH2:35]2)=[O:28])[S:14]12-(2-(2-(2-(Dimethylamino)ethylamino)-3-fluorophenyl)-3-(3,3-dimethylbutyl)-4-oxothiazolidin-5-yl)acetic acid (125.5 mg, 0.295 mmol), 1-(piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one (171.8 mg, 0.5900 mmol), EDC (113.1 mg, 0.5900 mmol), HOBt (90.35 mg, 0.5900 mmol), and DIEA (152.5 mg, 205.5 μL, 1.180 mmol) were stirred in DMF (6 mL) at RT overnight. The mixture was diluted with EtOAc and washed with water and a saturated sodium bicarbonate solution. The aqueous layer was back extracted, all organic layers were combined, washed with brine, dried over (MgSO4), concentrated to an oil. The crude oil was purified by reverse phase column chromatography with ACN/water to give desired 1-(1-(2-((5S)-2-(2-(2-(dimethylamino)ethylamino)-3-fluorophenyl)-3-(3,3-dimethylbutyl)-4-oxothiazolidin-5-yl)acetyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one.